Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses maintenance chemotherapy…
Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow…
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
Craig L. Slingluff Jr, MD, director of surgical oncology at the Emily Couric Clinical Cancer Center at the University of Virginia, discusses the use of seviprotimut-L vaccine against…
Yousef Zakharia, MD, clinical associate professor of internal medicine at the University of Iowa Holden Comprehensive Cancer Center, discusses completing a recent phase 1 trial studying seleno-L-methionine (SLM)…
Elizabeth R. Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology, director of Genitourinary Clinical Research, and professor in the Department of Hematology/Oncology at Fox Chase…
Bradley McGregor, MD, clinical director at Lank Center for Genitourinary Oncology, senior physician at Dana-Farber Cancer Institute, and instructor of medicine at Harvard Medical School, discusses a new…
Daniel George, MD, questions whether debulking nephrectomy is still necessary in the age of targeted therapies. In a one-sided non-inferiority study, sunitinib alone was compared to nephrectomy. The…
This video includes information related to immunoglobulin therapy for primary immunodeficiencies. The AAAAI has developed 8 guiding principles for the effective use of IVIG for patients with primary…
